Clinical study on drug holiday with regulated rheumatoid arthritis activity after treatment with tofacitinib (Xanadu study)

Clinical study on drug holiday with regulated rheumatoid arthritis activity after treatment with tofacitinib (Xanadu study) - Clinical study on rheumatoid arthritis treated with tofacitinib

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015462

Enrollment

400

Registered

2014-10-17

Start date

2014-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Continue current treatment Tofacitinib discontinuation MTX discontinuation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients that qualify the criteria below would be a candidate; 1) Rheumatoid arthritis was diagnosed following the 1987 or 2010 criteria 2) Rheumatoid arthritis patients treated with tofacitinib and SDAI<3.3 was observed at least 2 points (week-24 and -48) and is over 18 years old.

Exclusion criteria

Exclusion criteria: Patients judged as inadequate by the subinvestigator

Design outcomes

Primary

Measure	Time frame
SDAI remission, low disease activity rate DS28 remission rate, low disease activity rate	—

Secondary

Measure	Time frame
RF, MMP-3, CRP, ACPA, HAQ, Sharp score, adverse events	—

Countries

Japan

Contacts

Public ContactSatoshi Kubo

School of Medicine, University of Occupational and Environmental Health, Japan First Department of Internal Medicine

kubosato@med.uoeh-u.ac.jp093-603-1611

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026